Abstracts tagged "disease-modifying antirheumatic drugs and psoriatic arthritis"

Abstract Number: 2478 • 2019 ACR/ARP Annual Meeting
Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan
Daniel Aletaha¹, Patrick Zueger ², Naijun Chen ² and Nicola Booth ³, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Enthesitis, a symptom commonly associated with psoriatic arthritis (PsA), negatively affects quality of life. Although enthesitis is routinely reported in randomized clinical trials of…
Abstract Number: 2143 • 2018 ACR/ARHP Annual Meeting
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Linh Truong¹ and Maida Wong², ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Division of Rheumatology, University of California, Irvine, Orange, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…
Abstract Number: 2217 • 2012 ACR/ARHP Annual Meeting
Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients
Frank Behrens¹, Michaela Koehm¹, Diamant Thaci², Brigitte Krummel-Lorenz³, Gerd Greger⁴, Bianca Wittig⁴ and Harald Burkhardt⁵, ¹CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ²Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, ³CIRI/Endokrinologikum, Frankfurt/Main, Germany, ⁴Abbott GmbH & Co KG, Wiesbaden, Germany, ⁵CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany
Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].